NovoCure Ltd (NVCR)
22.02
-0.25
(-1.12%)
USD |
NASDAQ |
May 31, 16:00
22.00
-0.02
(-0.09%)
After-Hours: 20:00
NovoCure Enterprise Value: 2.069B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 2.069B |
| May 30, 2024 | 2.096B |
| May 29, 2024 | 2.068B |
| May 28, 2024 | 2.101B |
| May 24, 2024 | 2.191B |
| May 23, 2024 | 2.100B |
| May 22, 2024 | 2.250B |
| May 21, 2024 | 2.148B |
| May 20, 2024 | 2.288B |
| May 17, 2024 | 2.066B |
| May 16, 2024 | 2.085B |
| May 15, 2024 | 1.965B |
| May 14, 2024 | 1.886B |
| May 13, 2024 | 1.634B |
| May 10, 2024 | 1.472B |
| May 09, 2024 | 1.435B |
| May 08, 2024 | 1.425B |
| May 07, 2024 | 1.371B |
| May 06, 2024 | 1.373B |
| May 03, 2024 | 1.290B |
| May 02, 2024 | 1.227B |
| May 01, 2024 | 1.070B |
| April 30, 2024 | 1.017B |
| April 29, 2024 | 1.077B |
| April 26, 2024 | 1.059B |
| Date | Value |
|---|---|
| April 25, 2024 | 1.016B |
| April 24, 2024 | 1.027B |
| April 23, 2024 | 996.70M |
| April 22, 2024 | 972.49M |
| April 19, 2024 | 1.000B |
| April 18, 2024 | 996.16M |
| April 17, 2024 | 996.16M |
| April 16, 2024 | 1.040B |
| April 15, 2024 | 1.068B |
| April 12, 2024 | 1.160B |
| April 11, 2024 | 1.219B |
| April 10, 2024 | 1.273B |
| April 09, 2024 | 1.301B |
| April 08, 2024 | 1.225B |
| April 05, 2024 | 1.178B |
| April 04, 2024 | 1.237B |
| April 03, 2024 | 1.251B |
| April 02, 2024 | 1.248B |
| April 01, 2024 | 1.366B |
| March 31, 2024 | 1.381B |
| March 28, 2024 | 1.332B |
| March 27, 2024 | 1.226B |
| March 26, 2024 | 1.058B |
| March 25, 2024 | 1.072B |
| March 22, 2024 | 1.073B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
836.10M
Minimum
Nov 10 2023
23.02B
Maximum
Jun 23 2021
8.199B
Average
7.573B
Median
Enterprise Value Benchmarks
| AtriCure Inc | 1.047B |
| Perspective Therapeutics Inc | 680.29M |
| Xtant Medical Holdings Inc | 116.30M |
| Asensus Surgical Inc | 52.33M |
| Catheter Precision Inc | 2.370M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.76M |
| Revenue (Quarterly) | 138.50M |
| Total Expenses (Quarterly) | 180.02M |
| EPS Diluted (Quarterly) | -0.36 |
| Gross Profit Margin (Quarterly) | 75.68% |
| Profit Margin (Quarterly) | -27.98% |
| Earnings Yield | -8.22% |
| Normalized Earnings Yield | -8.220 |